EUVIMEDEUVIMED entdecken
Crossref

Salvage Therapy in Multiple Myeloma With Prior T‐Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide

James Di Palma-Grisi iD, David Vesole, David Siegel, Noa Biran iD, Pooja Phull, Harsh Parmar

European Journal of Haematology · 2026-06 · 116 (6) · 883-888

DOI: 10.1111/ejh.70151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 27.02.2026. Verfasst von James Di Palma-Grisi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hackensack University Medical Center, Hackensack, New Jersey, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocols, T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is a hematologic malignancy manifested by proliferation of clonal plasma cells leading to end‐organ damage. Despite significant advancements in therapeutics, it remains incurable. Cellular therapies such as chimeric antigen receptor (CAR‐T) therapy and T‐cell engager (TCE) therapies have delivered high overall response rates, but almost all patients relapse and subsequent options are limited particularly in view of the increasing prevalence of prior exposure to anti‐BCMA agents and immunomodulator (IMiD) therapies. Our retrospective review of 12 patients between January 2024 and December 2025 who received a combination of talquetamab, elranatamab, or teclistamab with pomalidomide found that 11 of 12 had an overall response, of whom 6 had very good partial response or better at median follow‐up of 9.9 months. All 12 patients were prior exposed to pomalidomide, of whom 10 had been exposed to prior CAR‐T with a median of 7 prior lines of therapy. Safety profiles were favorable: 6 patients experienced Grade 1 CRS, 7 experienced Grade III neutropenia, and 7 of 8 patients receiving talquetamab experienced on‐target, off‐tumor side effects like dysgeusia and skin dryness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaSalvage TherapyAntineoplastic Combined Chemotherapy ProtocolsT-LymphocytesHumansFemaleThalidomideMaleMiddle AgedTreatment OutcomeAgedRetrospective StudiesCombined Antibody TherapeuticsAntibodies, Bispecific

Substanzen

pomalidomideThalidomideCombined Antibody TherapeuticstalquetamabAntibodies, Bispecific

Autor:innen und Institutionen

  • Hackensack University Medical Center, Hackensack, New Jersey, USA.
  • John Theurer Cancer Center, Hackensack, New Jersey, USA.

ORCID-Profile: James Di Palma-Grisi, Noa Biran

Zitieren

APA

Di Palma-Grisi, J., Vesole, D., Siegel, D., Biran, N., Phull, P., & Parmar, H. (2026). Salvage Therapy in Multiple Myeloma With Prior T‐Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide. European Journal of Haematology, 116(6), 883-888. https://doi.org/10.1111/ejh.70151

Vancouver

Di Palma-Grisi J, Vesole D, Siegel D, Biran N, Phull P, Parmar H. Salvage Therapy in Multiple Myeloma With Prior T‐Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide. European Journal of Haematology. 2026;116(6):883-888. doi:10.1111/ejh.70151

BibTeX
@article{DiPalmaGrisi2026,
  author = {Di Palma-Grisi, James and Vesole, David and Siegel, David and Biran, Noa and Phull, Pooja and Parmar, Harsh},
  title = {Salvage Therapy in Multiple Myeloma With Prior T‐Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {116},
  number = {6},
  pages = {883--888},
  doi = {10.1111/ejh.70151}
}
Kostenlos starten →